Monthly Archives: July 2016

UPCOMING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against CBL & Associates Properties Inc. and Reminds Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 18, 2016 / Lundin Law PC announces a class action lawsuit has been filed against CBL & Associates Properties Inc. (“CBL” or the “Company”) (NYSE: CBL) concerning possible violations of federal securities laws between August 8, 2013 and May 24, 2016 (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the July 26, 2016 lead
plaintiff motion deadline.

To participate in this class action lawsuit, click here to participate. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the complaint, the Company made materially false and misleading statements and/or failed to disclose that: some of its employees may have provided material non-public information to Senator Robert Corker; CBL failed to disclose to its shareholders that certain of its financing arrangements may have been obtained through fraud; and as a result of the above, the company’s public statements were materially false and misleading. On May 24, 2016 the Wall Street Journal reported that the Federal Bureau of Investigation and the U.S. Securities and Exchange Commission were investigating whether CBL officials inflated rental income information on financial statements to banks when applying for financial arrangements. When this news was announced, CBL’s stock price fell.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 442536

Contest To Win Christian Guitar Lessons Launched

July 18, 2016 – – Jean Welles Worship Guitar, a business in Los Angeles, CA, has recently launched a new contest. The contest, which ends on July 24, 2016, enables people to win guitar lessons for Christian music in the form of DVDs, called ‘Jean Welles Worship Guitar Class’. After entering, those who are able to earn over 100 points will also get another of their guitar instructional programs for free. Registering for the contest can be done online at http://www.worshipguitarclass.com/wgc-lessons-contest.html.

Jean Welles, founder of Jean Welles Worship Guitar, says: “I want to share my love for the guitar, and my love of Christ, with the world, and I want to encourage others to do the same. I have created a four part series of instructional videos to teach people how to play worship songs on their guitar properly and comfortably. The contest only requires people to share on social media in order to have a chance to win.”

To earn points in the contest, participants and supporters share the contest on social media, where each referral is counted as 15 points. Registering for the contest is very simple and only requires people to enter their details. Jean Welles says that learning to play a musical instrument is good for your brain and learning worship music elevates the music to another dimension. Her goal is solely to enable people to learn how to be better musicians in servitude of Christ.

Besides guitar lessons, Jean Welles also offers worship guitar for children, playing piano by ear, music theory, Christian drum courses, and a piano course for Christians. Furthermore, she offers anyone who registers for her newsletter a free eBook on guitar playing tips and chord charts, to help that person get started with his or her guitar playing. People can register for the newsletter at http://www.worshipguitarclass.com.

Jean Welles Christian Guitar Lessons is also available on Facebook. “I want to have a strong focus on social media, as it enables me to communicate with more people and spread the message of our Lord,” adds Jean Welles. “This is also why I have focused my contest on social media sharing.”

###

Contact Jean Welles Worship Guitar:

Jean Welles
800-391-5412
jean@worshipguitarclass.com
11664 National Blvd #275
Los Angeles, CA 90064

ReleaseID: 60011353

Kentucky IVC Filter Users File Lawsuit Against Device Manufacturers, Cook Medical And Boston Scientific

July 18, 2016 – – TheProductLawyers.com reports on recent IVC filter lawsuit cases that plaintiffs have filed against the device’s manufacturers, linking the devices to detrimental, and even life-threatening side effects. New reports have indicated that Boston Scientific and Cook Medical have been named in several more IVC lawsuit cases in Kentucky. Both Kentucky lawsuits (5:16-cv-00065 & 5:16-cv-00066) accuse manufacturers of making defunct devices which left patients with deep vein thrombosis with dangerous blockages. Additionally, both plaintiffs have alleged that defunct IVC filters caused them significant amounts of pain after being implanted.

IVC Filters have been used by patients to reduce the risk of blood clots, along with the extensive damage that blood clots can have if they reach the pulmonary artery. In the situation where a clot reaches the pulmonary artery, patients are at a far greater risk for pulmonary embolism, heart failure, and or stroke. The devices have been utilized since 1979, where initially 2,000 people utilized IVC filters to combat the risk of pulmonary embolism. In 2007, about 167,000 IVC filters were being used to trap clots, and data suggests that the number of users has continued to increase in recent years.

However, as IVC filter users have increased, a number of patients have alleged that the devices can have devastating unknown side effects. Patients have since filed multiple lawsuits against C.R. Bard and Cook Medical, who both manufacturer the devices, that plaintiffs have claimed broke apart within their bodies. Furthermore, plaintiffs allege that broken pieces of the devices have begun to migrate within their bodies toward vital organs, which they claim heavily increases the risk of puncturing vital tissues and causing life-threatening damage.

In a multitude of cases, patients that were injured by IVC filters have formed a litigation, and plaintiffs claim that the device manufacturers did not provide adequate warnings to potential users. Moreover, IVC filter lawsuit plaintiffs also claim that several IVC filter manufacturers have continued to market the devices despite growing allegations, placing more potential users at risk. Cases have been combined in Multidistrict Litigations (No. 2641, & No. 2570) in the U.S. District Court of Arizona, as well as the Southern District of Indiana.

For more information on IVC filters, to ask questions or to schedule a consultation, contact an attorney at Banville Law by calling (888) 997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60011395

Talcum Powder Lawsuit Plaintiff Seeks Centralization of Federal Ovarian Cancer Claims, Bernstein Liebhard LLP Reports


July 18, 2916 – A talcum powder lawsuit (http://www.rxinjuryhelp.com/talcum-powder/johnson-johnson-baby-powder-lawsuit/) plaintiff has filed a motion with the U.S. Judicial Panel on Multidistrict Litigation (JPML) which seeks the centralization of all federally-filed ovarian cancer claims in a single court for the purposes of coordinated pretrial proceedings. According to a Motion for Transfer filed with the Panel on July 15th, the plaintiff has suggested the U.S. District Court, Southern District of Illinois, as the most appropriate venue for the proposed multidistrict litigation. (Case Pending No. 70)

Court records indicate that at least 11 product liability claims involving talcum powder and ovarian cancer have already been filed in 10 federal jurisdictions. Among other things, the Motion points out that the current plaintiffs reside in several different states, and it asserts that the Southern District of Illinois “would permit convenient travel for the parties and counsel as compared to travel to the East or West Coast.”

“The Johnson & Johnson talcum powder litigation already exceeds 1,200 cases on the state level. The federal docket also has the potential to be large, and would likely benefit from centralization, as coordinated pretrial proceedings would eliminate duplicative discovery and inconsistent court rulings,” says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices, drugs and consumer products. The Firm is offering free legal reviews to women who were diagnosed with ovarian cancer following years of regular, repeated use of talc-based products for feminine hygiene purposes.

Talcum Powder Ovarian Cancer Litigation
All of the talcum powder lawsuits currently pending in federal courts similarly allege that regular, repeated application of Johnson & Johnson’s Baby Powder and Shower-to-Shower products to the genitals can increase a woman’s risk for ovarian cancer. The complaints purport that talc particles can make their way into the vagina and migrate to the ovaries when used in this manner. Over time, the accumulating talc can result in the type of inflammation that promotes the growth of cancer cells. While a number of studies published since the 1970s have suggested such a link, plaintiffs claim that Johnson & Johnson has failed to take any steps to warn women of this possible risk.

More than 1,200 talcum powder lawsuits have been filed against Johnson & Johnson nationwide, with centralized litigations already underway in St. Louis, Missouri and New Jersey Superior Court. In April, a St. Louis jury awarded $55 million in compensatory and punitive damages to an ovarian cancer victim who used Johnson & Johnson’s talc-based powders for nearly 40 years as part of her feminine hygiene routine. In February, another Missouri trial ended with an award of $72 million for the family of a woman who died from the disease after using the company’s talc products for more than 30 years. (Case No. 1422-CC09012-01)

Women who were diagnosed with ovarian cancer following the long-term, regular use of talc-based products for feminine hygiene purposes may be eligible to file their own talcum powder lawsuit. To learn more, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to arrange for a free, no obligation case review.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal’s “Plaintiffs’ Hot List,” recognizing the top plaintiffs firms in the country. This year’s nomination marks the thirteenth year the firm has been named to this prestigious annual list.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2016 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com
http://www.rxinjuryhelp.com/
https://plus.google.com/115936073311125306742?rel=author

GET IN TOUCH
Sandy Liebhard
RX Injury Help
800-511-5092
http://www.rxinjuryhelp.com/

Release ID: 247849

IVC Filter Lawsuit Filings Continue, As FDA Clarifies Previous Safety Reports And Warnings

July 18, 2016 – – TheProductLawyers.com reports on updated information regarding the use of IVC filters as specifically issued by the U.S. Food and Drug Administration (FDA). The focus of the FDA public safety communications has been related to the duration of time that IVC filters should remain in a patient’s body and the dangers associated their use.

The first FDA safety warning was issued in August of 2010 related to the removal and retrieval of Inferior Vena Cava Filters. This particular communication was directed at surgeons and other medical professionals reminding them that the filters needed to be removed as soon as possible after the threat of pulmonary embolism had passed.

The second release was a clarification to the August communication released in May 2015 which stated that the filters should be removed from patients within 29-54 days following implantation unless the danger of the patient suffering a pulmonary embolism still exists. During the time that this communication was released, the FDA also mandated that companies manufacturing IVC filters take part in two studies that were intended to research the benefits and risks of using IVC filters.

It should be noted that the FDA has received 921 adverse event reports related to the use of IVC filters, which has prompted the issuance of the safety communications. The agency received these reports during the period of time from 2005 to August 2010.

Banville Law is currently looking to assist those individuals who believe they have suffered significantly from the use of an IVC filter.The firm strongly believes in leveling the playing field by pursuing justice for those who have been affected by dangerous devices or drugs.Qualifying persons may be entitled to legal action and significant financial compensation. Banville Law has years of experience fighting large pharmaceutical companies who have put dangerous drugs or devices into the market.

For more information on IVC filters, to ask questions or to schedule a consultation, contact an attorney at Banville Law by calling (888) 997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60011394

Personal Injury Lawyer Commends OSHA After Investigation Into Fall

July 18, 2016 – – LipsigLawyers.com’s Thomas Moverman recently stated the OSHA should be commended for their investigation into a worker’s fall. Moverman said that without organizations like the OSHA, workers in the construction industry would be at even higher risks of injury or death while on the job.

According to the Weekly Citizen, while a 54-year-old worker, who fell more than 11 feet as he installed a roof joist, recovered from his injuries, federal inspectors investigating his fall in March, arrived two days later and found a coworker about 40 feet off the ground without proper fall protection. The OSHA cited the company for violations and the company faces $40,000 in proposed fines.

The most common forms of injury in the construction business include slips, trips, and falls. These types of accidents in addition to electrocution and being stuck between objects or struck by them, accounted for over half of construction worker deaths in 2014, according to the Bureau of Labor Statistics. The OSHA reported that more than 20 percent of all work-related fatalities in 2013 were employed in the construction industry and that one in five of the 4,821 reported fatalities in 2014 were also in the construction industry.

Lipsig, Shapey, Manus & Moverman have been representing victims of construction accidents for years. The firm is currently looking to assist those individuals who have been injured in a construction accident and qualifying individuals may be entitled to financial compensation. They have successfully obtained millions in settlements for those victims and strongly believe in fighting for the compensation victims need and deserve. In one case, Attorney Thomas Moverman won a victim $2.6 million for a worker who injured his knee and back in a fall from defective scaffolding.

“Most of these actions help to make our environment and the workplace safer so that others will not have to endure these painful losses,” said Moverman of the firm’s work.

For more information on construction injuries, or for a free consultation, contact an attorney with Lipsig, Shapey, Manus & Moverman at (646)-846-4496.

###

Contact LipsigLawyers.com:

Marc Freund
877-711-9545
mfreund@lipsig.com
40 Fulton St, New York, NY 10038

ReleaseID: 60011424

SecondaryID: 7ccb14ad50ee999e

IVC Filter Manufacturer C.R. Bard Subject Of IVC Filter Lawsuit

July 18, 2016 – – TheProductLawyers.com reports on numerous allegations made by many plaintiffs against C.R. Bard claiming that the IVC filters the company manufactures are dangerous and defective. The company is the subject of approximately 50 lawsuits that cite the G2 and Recovery brand filters that it manufactures. These 50 cases have been consolidated into a federal litigation in Arizona.

One of these cases was originally filed in the U.S. District Court for the Eastern District of Missouri by a woman who claims her husband died as a result of a defective IVC filter. Her husband had a G2 IVC filter implanted in his inferior vena cava vein in November of 2006 with the purpose of preventing blood clots from migrating from his lower body to his heart and lungs. According to the court documents, after the implantation surgery, the filter tilted and subsequently tore the vena cava vein allowing blood clots to bypass the filter and reach his heart and lungs. In September 2012 he died as a result of a blood clot that proved to be fatal.

Generally, IVC filters are used in patients that cannot take traditional blood-thinning medications. The devices are surgically implanted into the inferior vena cava vein which transports blood from the lower body to the upper body, specifically and most importantly to the heart and lungs. The filters are meant to capture blood clots traveling to these major organs and hold them until they naturally dissipate. If a blood clot were to reach the heart or lungs it could cause significant and life-threatening harm to the patient.

Banville Law is currently looking to assist those individuals who believe they have suffered significantly from the use of an IVC filter. The firm strongly believes in leveling the playing field by pursuing justice for those who have been affected by dangerous devices or drugs. Qualifying persons may be entitled to legal action and significant financial compensation. Banville Law has years of experience fighting large pharmaceutical companies who have put dangerous drugs or devices into the market.

For more information on IVC filters, to ask questions or to schedule a consultation, contact an attorney at Banville Law by calling (888) 997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60011393

SecondaryID: 7ccb14ad50ee999e

NIKOS Announces Positive Results of Geochemical and Geophysical Surveys

VANCOUVER, BC / ACCESSWIRE / July 18, 2016 / Nikos Explorations Ltd. (TSXV: NIK) (“Nikos”) is pleased to announce the results of a soil gas hydrocarbon (“SGH”) survey recently completed at its Borden Lake Extension Project near Chapleau, Ontario. The SGH survey was completed over an area where up to 48 gold grains were found in till samples (see news release dated March 29, 2016) in order to identify anomalies that may be associated with gold mineralization in areas of poor outcrop up ice of the anomalous till samples.

Several SGH anomalies, potentially indicative of gold mineralization, were identified by Actlabs of Ancaster, Ontario, following its analysis. The interpretation suggests the anomalies have a confidence rating of 5.0 (out of a maximum of 6.0) based on the interpretation of SGH pathfinder classes known to be associated with buried gold deposits. A large number of SGH gold pathfinder maps provided further evidence for the positive interpretation of the SGH data.

This SGH anomalies occur approximately 250 metres up ice of the location of the anomalous till sample that contained 48 gold grains. In addition, they are coincident with a resistivity low identified during a recent infill VLF-EM survey (See maps at http://nikosexplorations.com/projects/borden_lake/). The infill VLF-EM survey also outlined similar resistivity lows in the area up ice of three anomalous till samples to the northwest.

“We are very pleased with the response from the SGH survey suggesting the presence of gold mineralization immediately up ice of our anomalous till samples and coincident with a VLF anomaly. It is especially significant given the proximity to Goldcorp’s Borden Lake Deposit,” said Roger Moss, Nikos President and CEO. “We are currently planning further surveys in this area to delineate drill targets.”

The company is finalizing plans for an induced-polarization/resistivity survey over the anomalous area to enable definitive drill targeting for testing in the fall.

About Borden Lake Extension:

The Borden Lake Extension Project covers an area of 36 square kilometres and lies approximately 5 km southeast of Goldcorp’s Borden Lake high grade gold zone where exploration has defined underground constrained indicated resources of 1.6 MMoz grading 5.39g/t Au and inferred resources of 0.4 MMoz grading 4.37 g/tAu. This zone remains open along strike to the southeast. In addition, a lower grade pit constrained indicated resource of 2.3 MMoz grading 1.03g/t gold has been defined. Exploration carried out by Nikos is the first known work on the property, which is located in the Kapuskasing Structural Zone. Nikos holds an option to earn a 100% interest in the property.

About Nikos Explorations:

Nikos Explorations is a Canadian based mineral exploration company focused on the acquisition and exploration of prospective gold projects in the Americas. The company has 17,881,741 shares issued and outstanding and trades on the TSX Venture Exchange under the symbol NIK.

Roger Moss, PhD., P.Geo., is the qualified person for all technical information in this release.

For more information please contact Roger Moss, President (416-704-8291) or Jim Borland, Director (416-272-7387), or visit our website at http://www.nikosexplorations.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

SOURCE: Nikos Explorations Ltd.

ReleaseID: 442534

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors in Lipocine Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 30, 2016 – LPCN

NEW YORK, NY / ACCESSWIRE / July 18, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Lipocine Inc. (“Lipocine” or “the Company”) (NASDAQ: LPCN) between June 30, 2015 and June 28, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey. To get more information go to: http://www.zlk.com/pslra/lipocine-inc or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the Class Period, defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Lipocine’s filing of its New Drug Application for LPCN 1021, Lipocine’s lead product candidate, contained deficiencies; and (2) as a result, defendant’s statements about Lipocine’s business and operations were false and misleading and/or lacked a reasonable basis.

On June 29, 2016, Lipocine announced that the U.S. Food and Drug Administration had issued a Complete Response Letter regarding the Company’s New Drug Application for LPCN 1021. According to the Complete Response Letter, the FDA has identified deficiencies related to the dosing algorithm for the label and concluded the application was not ready for approval in its present form.

If you suffered a loss in Lipocine you have until August 30, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 442517

Nascent Biotech and Hisun Announce an Exclusive License Agreement for the Development and Commercialization of Nascent’s Primary Asset, Pritumumab, in Mainland China

Development Planned for Multiple Epithelial Cancer Types, Starting with Brain Cancer, In Mainland China

TAIZHOU, ZHEJIANG PROVINCE, CHINA & VERO BEACH, FL / ACCESSWIRE / July 18, 2016 / Nascent Biotech, Inc. (OTC: NBIO), and Zhejiang Hisun Pharmaceutical Company Ltd., today announced they have entered into an exclusive licensing agreement for the development and commercialization of Nascent’s primary asset, Pritumumab, a monoclonal antibody for the treatment of epithelial cancers (which include brain, pancreas, colon, lung and breast), in mainland China. The agreement between the two companies licenses development, manufacture and commercialization rights for Pritumumab to Hisun, for the treatment of epithelial cancers in China.

“There are significant unmet medical needs in a variety of cancers,” said Sean Carrick, President of Nascent Biotech. “Nascent is committed to changing patient expectations in some of the world’s most debilitating cancers, and licensing Pritumumab to Hisun for therapeutic use in China will bring this promising treatment to significantly more patients who are in need. We’re highly encouraged by the potential of Pritumumab to deliver an innovative, first-in-class treatment option, and we are delighted to be working closely with Hisun in this collaboration.”

Mr. Bai Hua, Chairman of Hisun, expressed that licensing this promising biotech asset will enable Hisun to significantly move forward its goal of diversifying its product portfolio with branded and generic products and achieving Hisun’s long-term vision of “becoming a widely respected international pharmaceutical company” by “persisting in pharmaceutical innovation for the benefit of human beings.”

Under the terms of the agreement, Nascent Biotech will provide to Hisun its Master Cell Bank and related technology, which will allow Hisun to quickly begin manufacturing and further clinical development of Pritumumab in China.

“We are confident that this license agreement will allow Hisun to rapidly fill an unmet need in the cancer space while enabling Nascent to continue to advance this valuable asset in the US. Both companies will benefit greatly from this License arrangement,” added Dr. Haibin Wang, Senior Vice President, Head of Hisun Biopharmaceutical.

About Zhejiang Hisun Pharmaceuticals

With Revenues over $2 Billion annually, Hisun was founded in 1956, the vision of Zhejiang HISUN Pharmaceuticals Co., Ltd. (stock code 600267 – hereinafter called “HISUN”) is to become “a widely respected international pharmaceutical company” by advancing its mission of “persisting in pharmaceutical innovation for the benefit of human beings.” It focuses on the integration of pharmaceutical research and development (R&D) with production resources in order to provide its global customers with outstanding products and services. Visit http://www.hisunpharm.com.

About Nascent Biotech Inc

Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.

Safe Harbor:

Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Contact Information:

Nascent Biotech, Inc.

Sean Carrick
President | CEO

772.713.0541
sean.carrick@nascentbiotech.com
www.nascentbiotech.com

SOURCE: Nascent Biotech, Inc.

ReleaseID: 442516